The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The consensus price target hints at a 73.3% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Point72 Asset Management LP Point72 Asset Management LP | 101,278 | $1.84M | $1.11M | -$729,235.88 | -39.57% |
Joseph Castro Nuveen LLC | 29,464 | $253,390 | $324,071.59 | $70,681.59 | 27.89% |
| TC Thomas Cagna Sandia Investment Management LP | 10,000 | $185,000 | $110,915 | -$74,085 | -40.05% |
| RO Regan O'Neill Burkehill Global Management LP | 50,000 | $925,000 | $549,750 | -$375,250 | -40.57% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 17 | $146 | $192.27 | $46.27 | 31.69% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Caitlin Zulla CEO | NASDAQ (NGS) Exchange | 550249106 CUSIP |
| US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |